Infex reports Phase IIa win for anti-Pseudomonas antibody
A new monoclonal antibody approach could add an infection-directed option to the changing treatment landscape for non-cystic fibrosis bronchiectasis.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1569 entries already.
Entries by Thomas Gabrielczyk
SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
/in News/by Thomas GabrielczykSERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug.
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet
/in News/by Thomas GabrielczykHarbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
$55m financing round for NVision
/in News/by Thomas GabrielczykWith $55m in fresh capital, Ulm-based NVision is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s anchor investor.
Millions for Preclinical Immunology: Boehringer Teams Up with Immunitas
/in News/by Thomas GabrielczykGerman Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the growing race for selective immune-cell depletion approaches — and adds another strategic win for Novartis-, Merck-, Bayer- and Evotec-backed Immunitas.
Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive
/in News/by Thomas GabrielczykIsomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.
Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
/in News/by Thomas GabrielczykInfex Therapeutics has raised £4.3 million (€4.95 million) to advance an anti-infective pipeline led by a midphase drug candidate.
EktaH links novel obesity drug to fat loss, muscle retention in early-phase trial
/in News/by Thomas GabrielczykEktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year.
Tolemy Bio raises €1.4m to build AI control panel for cell biology
/in News/by Thomas GabrielczykCambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic processes.
Angelini inks $4.1B Catalyst takeover to fuel US expansion
/in News/by Thomas GabrielczykItaly’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market.